Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-010992
Filing Date
2019-11-14
Accepted
2019-11-14 08:22:06
Documents
69
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ruby-20190930x10q.htm 10-Q 2582810
2 EX-10.2 ruby-20190930ex1029429b0.htm EX-10.2 68029
3 EX-31.1 ruby-20190930ex311ae8a8b.htm EX-31.1 12743
4 EX-31.2 ruby-20190930ex312448826.htm EX-31.2 12594
5 EX-32.1 ruby-20190930ex321abdbcd.htm EX-32.1 8104
6 EX-32.2 ruby-20190930ex3225a28d7.htm EX-32.2 8092
  Complete submission text file 0001558370-19-010992.txt   7766493

Data Files

Seq Description Document Type Size
7 EX-101.INS ruby-20190930.xml EX-101.INS 1426296
8 EX-101.SCH ruby-20190930.xsd EX-101.SCH 50059
9 EX-101.CAL ruby-20190930_cal.xml EX-101.CAL 58624
10 EX-101.DEF ruby-20190930_def.xml EX-101.DEF 176307
11 EX-101.LAB ruby-20190930_lab.xml EX-101.LAB 482211
12 EX-101.PRE ruby-20190930_pre.xml EX-101.PRE 349625
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

EIN.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38586 | Film No.: 191216464
SIC: 2836 Biological Products, (No Diagnostic Substances)